<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349556</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00042104</org_study_id>
    <nct_id>NCT01349556</nct_id>
  </id_info>
  <brief_title>Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream</brief_title>
  <official_title>Prevention of Epidermal Growth Factor Receptor Inhibitor-Associated Dermatologic Toxicities by Pre-treatment With Topical Tretinoin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      This research is being done to study whether using of topical tretinoin can help prevent the
      common rash that patients often get while taking epidermal growth factor inhibitor (EGFR-I)
      medications such ascetuximab or erlotinib.

      Patients taking EGFR-I medications often develop skin irritation and acne-like bumps on their
      face, chest, and other areas. This rash from EGFR-I's is often treated with moisturizers and
      topical or oral antibiotics. However, there has not yet been a study looking at a way to
      prevent this common side effect from occurring, and topical tretinoin may be useful in
      reducing the rash.

      Tretinoin 0.025% cream is approved by the Food and Drug Administration (FDA) for the
      treatment of acne, acne scarring, and photodamage. It is not approved for use in preventing
      rashes associated with EGFR-I's.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn due to volunteer disinterest in participating.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EGFRi rash severity</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Medication Reaction</condition>
  <arm_group>
    <arm_group_label>Tretinoin pre-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin</intervention_name>
    <description>tretinoin 0.025% cream</description>
    <arm_group_label>Tretinoin pre-treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or over

          -  Scheduled to begin treatment with an EGFR inhibitor drug

        Exclusion Criteria:

          -  Pregnant or nursing

          -  History of bleeding disorder

          -  History of keloids or large, thick, puffy-looking scars in the last 10 years

          -  Used topical retinoids in the last year (e.g. tretinoin/Retin-A, adapalene/Differin,
             tazarotene/Tazorac)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna L Chien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Dermatology</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Anna Chien</investigator_full_name>
    <investigator_title>Assistant Professor, Co-Director, Cutaneous Translational Research Program</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>EGFR inhibitors</keyword>
  <keyword>tretinoin</keyword>
  <keyword>EGFRi drug rash</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

